Cardiol Therapeutics (CRDL) Gains from Investment Securities (2022 - 2026)
Cardiol Therapeutics' (CRDL) quarterly Gains from Investment Securities came in at -$109437.8 in Q2 2024, up 82.63% YoY from -$59921.8 in Q3 2023, and up 69.97% on a QoQ basis from -$364449.6 in Q1 2024.
Cardiol Therapeutics (CRDL) Gains from Investment Securities (2022 - 2026) Analysis & Trends
Cardiol Therapeutics (CRDL) has 3 years of Gains from Investment Securities data on file, last reported at -$109437.8 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Cardiol Therapeutics | 214.93 Mn | 196.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.12 Mn |
| Mar 31, 2026 | 1.12 Mn |
| Sep 30, 2024 | -991,150.52 |
| Sep 30, 2024 | -991,150.52 |
| Jun 30, 2024 | -109,437.85 |
| Jun 30, 2024 | -109,437.85 |
| Mar 31, 2024 | -364,449.57 |
| Mar 31, 2024 | -364,449.57 |
| Sep 30, 2023 | 722,212.12 |
| Sep 30, 2023 | 722,212.12 |
| Jun 30, 2023 | -630,201.35 |
| Jun 30, 2023 | -630,201.35 |
| Mar 31, 2023 | -2,041.56 |
| Mar 31, 2023 | -2,041.56 |
| Sep 30, 2022 | 2.46 Mn |
| Sep 30, 2022 | 2.46 Mn |
| Jun 30, 2022 | 1.42 Mn |
| Jun 30, 2022 | 1.42 Mn |
| Mar 31, 2022 | -1.10 Mn |
| Mar 31, 2022 | -1.10 Mn |